Early Access — free while we kick the tires
EdgarHawk

PTGX Protagonist Therapeutics, Inc Insider Trading

Latest: Director Sold $5.9M of Shares · May 2026
2 filings analyzed · Latest 2026-05-12
Insider buys
0
Insider sells
2
Unique insiders
2
Direction
Net selling
May 2026
2026-05-12
medium
Dinesh V Ph D Patel Sell
President and CEO
75,000 shares
$7,509,000
@ $100.12
Significance 4/10

CEO Dinesh Patel exercised options and sold all 75,000 shares same-day for $7.5M, offsetting his stock position while stock trades near 52-week highs.

Dinesh Patel, the company's President and CEO, executed a textbook option exercise-and-sell on the same day: acquiring 75,000 shares through a stock option exercise and immediately liquidating the entire position. The combined transactions netted approximately $5.9M in proceeds after acquisition costs. This is the 19th open-market sale Patel has executed in the past three years, continuing a persistent selling pattern with no open-market purchases during that same window. His prior sales at this company show mixed timing: four of his five most recent exits at PTGX were poorly timed (the stock rose afterward), while one was well-timed (the stock fell). The current sale occurs while the stock trades near its 52-week high following a sharp rally over the prior three months, though the company's fundamentals remain stressed—it is unprofitable with significant revenue contraction. The exercise-and-sell structure is routine for options management, but the consistent avoidance of open-market purchases and the heavily tilted selling track record warrant noting.

2026-05-11
medium
Giraudo Bryan Sell
59,130 shares
$5,918,880
@ $100.10
Significance 5/10

Director Bryan Giraudo sells nearly $6M in PTGX stock while simultaneously exercising $238K in options—mixed signal from a board member with a strong buy-timing track record.

Director Bryan Giraudo exercised options to acquire 36,000 shares but then immediately sold 59,130 shares over two days, netting a disposition of roughly 23,000 shares worth nearly $6M. This two-sided transaction is contradictory: the option exercise suggests some conviction in the company's direction, yet the rapid and much larger sale signals a reduction in his equity exposure. Giraudo's prior trades show a strong history of well-timed purchases, with prior buys consistently delivering positive returns—yet this filing reverses that pattern by shifting to net seller status. The company's fundamentals are challenged, showing significant revenue contraction and a net loss, which provides some rationale for liquidating shares. Giraudo's placement of large sales on the open market after exercising newly-vested options suggests he may be executing a planned divestiture rather than responding to immediate price movement, especially given that the stock is trading only slightly below its 52-week high.

More Chemicals and Allied Products companies

Get alerts for PTGX

Add PTGX to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access